Reply to: "Ammonia and prognosis of cirrhosis: A new perspective for identifying high risk patients"
Reply to: "Ammonia and prognosis of cirrhosis: A new perspective for identifying high risk patients"
复制标题
回复：《氨与肝硬化预后：识别高危患者的新视角》
DOI：
10.1016/j.jhep.2022.10.025
复制
发表时间：
2023
影响因子：
25.7
通讯作者：
Tranah T
中科院分区：
文献类型：
--
作者：
Tranah T
利益冲突：Rajiv Jalan是OPA的发明者，OPA已由UCL申请专利，并授权给Mallinckrodt Pharma。他还是Yaqrit Discovery的创始人，该公司是伦敦大学学院、Hepyx Limited和Cyberliver的分拆公司。他与Yaqrit Discovery进行了研究合作。其他作者没有利益冲突需要声明
Conflicts of Interest: Rajiv Jalan is the inventor of OPA, which has been patented by UCL and licensed to Mallinckrodt Pharma. He is also the founder of Yaqrit Discovery, a spin out company from University College London, Hepyx Limited and Cyberliver. He had research collaborations with Yaqrit Discovery. The other authors have no conflicts of interest to declare